A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

GLP-1 agonist medications ... With the help of a healthcare provider, you can explore the best options for weight loss, including medications, diet, and exercise. On the Klarity platform, find ...

Research suggests this combination reduces side effects and vastly improves outcomes, including weight loss, compared to GLP-1 alone ... or low blood sugars. The best way to know if a medication ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...